Greetings from MyCancerHaven!
We wanted to update you on our recent activities.
We've added below videos to our Videos repository.
The video is titled
The Phase 3 AURIGA Study by Ashraf Badros MD from Professor of Medicine Director of the Multiple Myeloma Service University of Maryland School of Medicine , and it's been added/updated in Multiple Myeloma Category
Here are the latest posts last week:
Blogs :
Criteria for transitioning multiple myeloma patients from bispecifics to community care.
Quadruplets considered best option for transplant-ineligible multiple myeloma patients.
Protocols for monitoring and managing long-term bispecific therapy complications in myeloma.
Dr. Delforge explains CARTITUDE-4 rationale for lenalidomide-refractory myeloma treatment.
Resources required for improved bispecific therapy implementation.
Areas for improvement in real-world application of GPRC5D-targeted therapy.
Dr. Dimopoulos discusses DREAMM-8 trial results on multiple myeloma efficacy.
Also at MCH the News and Tweets never stop flowing!
Join Us at www.mycancerhaven.org
The Team @ MCH
Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok
Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.
We wanted to update you on our recent activities.
We've added below videos to our Videos repository.
The video is titled
The Phase 3 AURIGA Study by Ashraf Badros MD from Professor of Medicine Director of the Multiple Myeloma Service University of Maryland School of Medicine , and it's been added/updated in Multiple Myeloma Category
Here are the latest posts last week:
Blogs :
Criteria for transitioning multiple myeloma patients from bispecifics to community care.
Quadruplets considered best option for transplant-ineligible multiple myeloma patients.
Protocols for monitoring and managing long-term bispecific therapy complications in myeloma.
Dr. Delforge explains CARTITUDE-4 rationale for lenalidomide-refractory myeloma treatment.
Resources required for improved bispecific therapy implementation.
Areas for improvement in real-world application of GPRC5D-targeted therapy.
Dr. Dimopoulos discusses DREAMM-8 trial results on multiple myeloma efficacy.
Also at MCH the News and Tweets never stop flowing!
Join Us at www.mycancerhaven.org
The Team @ MCH
Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok
Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.
